Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
126 hot topic(s) found with the query "Depression"

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics
L Beunk et al, EJHG, March 31, 2023 (Posted: Mar-31-2023 7AM)

Even though evidence is limited, the DPWG recommends choosing an alternative drug to treat symptoms of depression or a dose reduction for other indications for quetiapine and CYP3A4 PMs. No therapy adjustments are recommended for the other CYP2D6 and CYP3A4 predicted phenotypes. In addition, no action is required for the gene-drug combinations CYP2D6 and clozapine, flupentixol, olanzapine or quetiapine and also not for CYP1A2 and clozapine or olanzapine.

Digital cognitive behavioral therapy for insomnia on depression and anxiety: a systematic review and meta-analysis
S Lee et al, NPJ Digital Medicine, March 25, 2023 (Posted: Mar-25-2023 8AM)

Despite research into the development of digital cognitive behavioral therapy for insomnia (dCBT-I), research into the outcomes of dCBT-I on insomnia and the associated clinical conditions of depression and anxiety have been limited. The PubMed, PsycINFO (Ovid), Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) on adult patients with insomnia also having reported measures of depressive or anxiety symptoms. We found that digital intervention for insomnia yielded significant effects on alleviating depressive and anxiety symptoms as well as insomnia symptoms. Specifically, the study demonstrated significant effects on the above symptoms when considering treatment adherence and implementing fully automated dCBT-I.

Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives
XG Gonzalez et al, J Pers Med, February 22, 2023 (Posted: Feb-22-2023 6AM)

Huntington’s disease (HD) is an autosomal dominant progressive brain disorder, caused by a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic neurodegenerative rare disease is characterized by cognitive, motor, and neuropsychiatric manifestations. The aim of the treatment is symptomatic and addresses the hyperkinetic disorders (chorea, dystonia, myoclonus, tics, etc.) and the behavioral and cognitive disturbances (depression, anxiety, psychosis, etc.) associated with the disease. HD is still a complex condition in need of innovative and efficient treatment.

Systematic review of economic evaluations for internet- and mobile-based interventions for mental health problems
F Kahlke et al, NPJ Digital Medicine, November 2022 (Posted: Nov-28-2022 11AM)

Of the 4044 studies, 36 economic evaluations were reviewed. Guided IMIs were likely to be cost-effective in depression and anxiety. The quality of most evaluations was good, albeit with some risks of bias. Heterogeneity across studies was high because of factors such as different costing methods, design, comparison groups, and outcomes used. IMIs for anxiety and depression have potential to be cost-effective. However, more research is needed into unguided (preventive) IMIs with active control conditions (e.g., treatment as usual) and longer time horizon across a wider range of disorders.

Parental Depression and Anxiety Associated with Newborn Bloodspot Screening for Rare and Variable-Onset Disorders
NB Boychuk et al, IJNS, November 10, 2022 (Posted: Nov-11-2022 6AM)

Clinical utility of pharmacogenetics in a psychiatric and primary care population
KN Bohlen et al, The PGX Journal, October 27, 2022 (Posted: Oct-27-2022 9AM)

This study evaluated the timing, use, and clinical outcomes of a pharmacogenomic panel in a healthcare setting with patients managed by primary care providers or by psychiatrists. Participants were randomized to receive a pharmacogenetics report at four weeks or 12 weeks. We found that mental quality of life, depression severity, and clinical outcomes were improved by pharmacogenomic testing regardless of provider type, with earlier testing improving outcomes sooner.

Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder
V Skryabin et al, The PGX journal, October 22, 2022 (Posted: Oct-24-2022 10AM)

Publications referring to genotype-guided antidepressant therapy were identified. We found that studies comparing clinical outcomes between two groups of patients who received antidepressant treatment were included in meta-analysis. Analysis of the data revealed statistically significant differences between the experimental group receiving pharmacogenetically guided dosing and the empirically treated controls. Specifically, genotype-guided treatment significantly improved response and remission of patients after both eight and twelve weeks of therapy,

Fitbit step counts clarify the association between activity and chronic disease risk
Nature Medicine, October 11, 2022 (Posted: Oct-12-2022 8AM)

Using electronic health records data from the All of Us Research Program, we show that higher daily step counts in data collected over several years of Fitbit fitness tracker use were associated with lower risk of common, chronic diseases, including diabetes, hypertension, gastroesophageal reflux disease, depression, obesity and sleep apnea.

Genome-by-Trauma Exposure Interactions in Adults With Depression in the UK Biobank.
Chuong Melisa et al. JAMA psychiatry 2022 9 (Posted: Sep-30-2022 7AM)

This cross-sectional study used an approach combining all genome-wide SNV data when exploring genome-by-trauma interactions in individuals with MDD; findings suggest that such interactions were associated with depression manifestation. Genome-by-trauma interaction accounts for greater trait variance in male individuals, which points to potential differences in depression etiology between the sexes. The methodology used in this study can be extrapolated to other environmental factors to identify modifiable risk environments and at-risk groups to target with interventions.

A systematic review of digital and face-to-face cognitive behavioral therapy for depression
NPJ Digital Medicine, September 15, 2022 (Posted: Sep-15-2022 7AM)

Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning: Dementia Praecox Revisited.
Koutsouleris Nikolaos et al. JAMA psychiatry 2022 8 (Posted: Aug-05-2022 8AM)

In this diagnostic/prognostic study including 1870 patients, patients with schizophrenia expressed the neuroanatomical pattern of behavioral-variant frontotemporal dementia more strongly (41%) than that of Alzheimer disease (17%), and at lower levels, this difference was also encountered in those with major depression (22% vs 3%). Already in clinical high-risk states for psychosis the high expression of the behavioral-variant frontotemporal dementia pattern was linked to severe phenotypes, unfavorable courses, and elevated polygenic risks for schizophrenia and dementia, with further pattern progression being present in those patients who did not recover over time.

Association of Everyday Discrimination With Depressive Symptoms and Suicidal Ideation During the COVID-19 Pandemic in the All of Us Research Program
YH Lee et al, JAMA Psychiatry, July 27, 2022 (Posted: Jul-27-2022 2PM)

In this cohort study, everyday discrimination was associated with significantly increased odds of moderate to severe depressive symptoms and suicidal ideation between May and July 2020. Notably, this association was stronger among participants self-identifying as Hispanic or Latino or non-Hispanic Asian when the main reason for discrimination was race, ancestry, or national origins.

Incorporating family history of disease improves polygenic risk scores in diverse populations
MLA Hujeol et al, Cell Genomics, July 13, 2022 (Posted: Jul-14-2022 7AM)

Polygenic risk scores (PRSs) derived from genotype data and family history (FH) of disease provide valuable information for predicting disease risk, but PRSs perform poorly when applied to diverse populations. Here, we explore methods for combining both types of information (PRS-FH) in UK Biobank data. We evaluated PRS, FH, and PRS-FH using liability-scale R2, primarily focusing on 3 well-powered diseases (type 2 diabetes, hypertension, and depression). PRS attained average prediction R2s of 5.8%, 4.0%, and 0.53% in non-British Europeans, South Asians, and Africans, confirming poor cross-population transferability. In contrast, PRS-FH attained average prediction R2s of 13%, 12%, and 10%, respectively, representing a large improvement in Europeans and an extremely large improvement in Africans. In conclusion, including family history improves the accuracy of polygenic risk scores, particularly in diverse populations.

Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome.
Diniz Breno S et al. JAMA network open 2022 6 (6) e2219678 (Posted: Jul-01-2022 8AM)

Are markers associated with the senescence-associated secretory phenotype (SASP) associated with treatment remission in older adults with major depressive episode? In this nonrandomized clinical trial of 416 participants, higher SASP index, a composite score of 22 biomarkers associated with the SASP, was significantly associated with lower likelihood of remission to antidepressant treatment.

Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes.
Soler Artigas María et al. International journal of epidemiology 2022 6 (Posted: Jun-18-2022 10AM)

We used genome-wide association study (GWAS) summary statistics for ADHD (n?=?53?293) and 124 traits related to anthropometry, cognitive function and intelligence, early life exposures, education and employment, lifestyle and environment, longevity, neurological, and psychiatric and mental health or personality and psychosocial factors available in the MR-Base database (16?067 =n?=766?345). Our findings strengthen previous evidence of a causal effect of ADHD liability on smoking and major depression, and are consistent with a causal effect on odds of decreased average total household income [odds ratio (OR)?=?0.966, 95% credible interval (CrI)?=?(0.954, 0.979)] and increased lifetime number of sexual partners [OR?=?1.023, 95% CrI?=?(1.013, 1.033)].

Effects of social support on depression risk during the COVID-19 pandemic: What support types and for whom?
KW Choi et al, MEDRXIV, May 16, 2022 (Posted: Jun-15-2022 9AM)

Machine learning of language use on Twitter reveals weak and non-specific predictions
SW Kelley et al, NPJ Digital Medicine, March 25, 2022 (Posted: Mar-26-2022 3PM)

Depressed individuals use language differently than healthy controls and it has been proposed that social media posts can be used to identify depression. Much of the evidence behind this claim relies on indirect measures of mental health and few studies have tested if these language features are specific to depression versus other aspects of mental health. We analysed the Tweets of 1006 participants who completed questionnaires assessing symptoms of depression and 8 other mental health conditions.

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression
J Wen et al, JAMA Psychiatry, March 9, 2022 (Posted: Mar-09-2022 11AM)

s late-life depression (LLD) associated with structural neuroimaging patterns? In this case-control study, 2 dimensions best represented neuroanatomical heterogeneity in patients with LLD: one was associated with preserved brain structure and the other demonstrated diffuse structural abnormalities and greater cognitive impairment. One de novo independent genetic variant was significantly associated with dimension 1 but not with dimension 2, and dimension 2 was longitudinally associated with Alzheimer disease and brain aging more than dimension 1.

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study
AI Campos et al, The PGX journal, January 29, 2022 (Posted: Jan-31-2022 9AM)

Digital health tools for the passive monitoring of depression: a systematic review of methods
V de Angel et al, NPJ Digital Medicine, January 10, 2022 (Posted: Jan-11-2022 8AM)

The literature is characterized by small sample sizes, short follow-up duration and great variability in the quality of reporting, limiting the interpretability of pooled results. Bivariate analyses show consistency in statistically significant associations between depression and digital features from sleep, physical activity, location, and phone use data. Machine learning models found the predictive value of aggregated features. Given the pitfalls in the combined literature, these results should be taken purely as a starting point for hypothesis generation.

Association between maternal depression during pregnancy and newborn DNA methylation
E Drzymalla et al, Trans Psychiatry, November 9, 2021 (Posted: Nov-10-2021 9AM)

Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19
CDC Science Brief, October 14, 2021 Brand (Posted: Oct-16-2021 8AM)

Chronic lung disease (including bronchiectasis, bronchopulmonary dysplasia, interstitial lung disease, pulmonary hypertension, pulmonary embolism, tuberculosis) and chronic liver disease (including cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021 using the updated review methods outlined below. Mental health disorders (such as mood disorders including depression, and schizophrenia spectrum disorders) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021. No conditions were removed from the previous underlying medical conditions list.

Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis.
Nikolova Viktoriya L et al. JAMA psychiatry 2021 9 (Posted: Sep-18-2021 11AM)

This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.

What is pharmacogenomics?
CB de Villiers, PHG Foundation, August 2021 (Posted: Aug-26-2021 7AM)

Pharmacogenomics, a branch of precision medicine, is the study of genomic characteristics that affect how individuals respond to drugs. It could be useful for improving treatment for a wide variety of conditions such as depression, schizophrenia, heart disease, diabetes, cancer, and infectious diseases.

Health Equity for People with Disabilities
CDC, July 2021 Brand (Posted: Jul-08-2021 8AM)

An estimated one in four, or 61 million adults in the United States reported a disability. People with disabilities (such mobility limitations, deafness and blindness, or intellectual disabilities) face many challenges to achieving optimal health and accessing high-quality health care. Data from 2019 shows, compared to people without disabilities, people with disabilities have less access to health care, have more depression and anxiety, engage more often in risky health behaviors such as smoking, and are less physically active.

Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology
N Mullins et al, Nature Genetics, May 17, 2021 (Posted: May-18-2021 8AM)

We performed a genome-wide association study of 41,917 bipolar disorder cases and 371,549 controls of European ancestry, which identified 64 associated genomic loci. Bipolar disorder risk alleles were enriched in genes in synaptic signaling pathways and brain-expressed genes, particularly those with high specificity of expression in neurons of the prefrontal cortex and hippocampus. Significant signal enrichment was found in genes encoding targets of antipsychotics, calcium channel blockers, antiepileptics and anesthetics.

Symptom-level modelling unravels the shared genetic architecture of anxiety and depression
JG Thorp et al, Nature Human Behavior, April 15, 2021 (Posted: Apr-19-2021 10AM)

Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.
Papastergiou John et al. Clinical and translational science 2021 (Posted: Mar-05-2021 9AM)

In this prospective, single-blind randomized controlled design, we evaluated the impact of pharmacogenomics guided versus standard antidepressant treatment of depression and anxiety, implemented in three large community pharmacies. Participants were 213 outpatients diagnosed with major depressive disorder and/or generalized anxiety disorder, randomized to receive pharmacogenomics guided (n = 105) or standard antidepressant treatment (n = 108).

A machine learning approach predicts future risk to suicidal ideation from social media data.
Roy Arunima et al. NPJ digital medicine 2020 May 3(1) 78 (Posted: Feb-23-2021 9AM)

Our objective was to generate an algorithm termed "Suicide Artificial Intelligence Prediction Heuristic (SAIPH)" capable of predicting future risk to suicidal thought by analyzing publicly available Twitter data. We trained a series of neural networks on Twitter data queried against suicide associated psychological constructs including burden, stress, loneliness, hopelessness, insomnia, depression, and anxiety. We used 512,526 tweets from N?=?283 suicidal ideation (SI) cases and 3,518,494 tweets from 2655 controls.

Risk of Early-Onset Depression Associated With Polygenic Liability, Parental Psychiatric History, and Socioeconomic Status.
Agerbo Esben et al. JAMA psychiatry 2021 Jan (Posted: Jan-14-2021 9AM)

In this case-cohort study of 17?098 patients with depression, the absolute risk of depression by the age of 30 years differed substantially depending on an individual’s combination of risk factors, ranging from 1.0% among male individuals with high socioeconomic status in the bottom 2% of the polygenic risk score distribution to 23.7% among female individuals in the top 2% of PRS with a parental history of psychiatric disorders.

Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders A Multivariable Mendelian Randomization Analysis
DB Rosoff et al, JAMA Psychiatry, November 11, 2020 (Posted: Nov-11-2020 11AM)

The findings of this mendelian randomization analysis suggest evidence for potential causal associations between the genetic liability for increased prescription opioid use and the risk for major depression. While replication studies are necessary, these findings may inform prevention and intervention strategies.

Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis
YS Wan et al, The Pharmacogenomics Journal, October 23, 2020 (Posted: Oct-24-2020 10AM)

The correlations between hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms (1438A/G, 102T/C, and rs7997012G/A) and the safety and efficacy of antidepressants in depression patients have been reported. This meta-analysis ascertained forty-two studies. Pooled analyses indicated significant associations of 1438A/G polymorphism and higher response.

Alexa, do I have COVID-19?
E AnNthes, Nature News, September 30, 2020 (Posted: Oct-02-2020 9AM)

Researchers are exploring ways to use people’s voices to diagnose coronavirus infections, dementia, depression and much more.

The association of alcohol polygenic risk scores with mental health outcomes: A multi-generational analysis in the Avon Longitudinal Study of Parents and Children
KE Easey et al, MEDRXIV, July 7, 2020 (Posted: Jul-08-2020 6AM)

An alcohol PRS derived from GWAS of alcohol use in the general population was shown to be associated with frequency and amount of alcohol consumed during pregnancy, and maternal depression at 32 weeks gestation.

Monitoring Depression Trend on Twitter during the COVID-19 Pandemic
Y Zhang et al, ARXIV, July 1, 2020 (Posted: Jul-02-2020 9AM)

Genetic Associations Between Childhood Psychopathology and Adult Depression and Associated Traits in 42 998 Individuals A Meta-analysis
WA Akingbuwa et al, JAMA Psychiatry, July 1, 2020 (Posted: Jul-02-2020 8AM)

This meta-analysis of longitudinal cohorts, which includes data on 42?998 participants, revealed significant associations between childhood psychopathology and adult polygenic scores of major depression, subjective well-being, neuroticism, insomnia, educational attainment, and body mass index but not bipolar disorder.

Grant Report on SCH: Personalized Depression Treatment Supported by Mobile Sensor Analytics.
Kamath Jayesh et al. Journal of psychiatry and brain science 2020 5 (Posted: Jun-16-2020 3PM)

A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety
D Richards et al, NPJ Digital Medicine, June 15, 2020 (Posted: Jun-16-2020 9AM)

Utilization of internet-delivered cognitive behavioral therapy (iCBT) for treating depression and anxiety disorders in stepped-care models, such as the UK’s Improving Access to Psychological Therapies (IAPT), is a potential solution for addressing the treatment gap in mental health.

Our phones can now detect health problems from Parkinson’s to depression. Is that a good thing?
L Parshley, VOX, February 2020 (Posted: Feb-21-2020 9AM)

Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders
F Till et al, Molecular Psychiatry, November 11, 2019 (Posted: Nov-12-2019 8AM)

Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
Kotsopoulos Joanne et al. Menopause (New York, N.Y.) 2019 Oct (Posted: Oct-30-2019 8AM)

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
C Fabri et al, MedRXIV, September 20, 2019 (Posted: Sep-20-2019 9AM)

Treatment-resistant depression occurs in ~30% of patients with major depressive disorder (MDD). Whole exome sequencing and genome-wide genotyping were performed in 1320 MDD patients. Response to the first pharmacological treatment was compared to non-response to one treatment and non-response to two or more treatments.

Powering discovery in blood disorders and depression
A Cranage, Sanger Institute, September 2019 (Posted: Sep-16-2019 8AM)

"UK Biobank data is so vast, and so detailed. It has changed the way we do research in human genetics. We are beginning not only to understand the complex genetic basis of a whole variety of devastating human diseases, but also how to better use this genetic information to understand how to predict and treat these diseases.”

A two-stage approach to identifying and validating modifiable factors for the prevention of depression
KW Choi et al, BioRXIV preprints, September 8, 2019 (Posted: Sep-10-2019 9AM)

As the field increasingly quantifies the role of genetic factors in complex conditions such as depression, knowledge of modifiable factors that could offset one’s genetic risk has become highly relevant. The authors present an approach to screening for potentially modifiable factors that may offset the risk of depression.

Can Machine Learning help us in dealing with treatment resistant depression? A review.
Pigoni Alessandro et al. Journal of affective disorders 2019 Aug 25921-26 (Posted: Aug-27-2019 7PM)

Using Electronic Health Records and Machine Learning to Predict Postpartum Depression.
Wang Shuojia et al. Studies in health technology and informatics 2019 Aug 264888-892 (Posted: Aug-27-2019 6PM)

Robin Williams' Son Zak Says He Struggled with Depression: 'I Found Myself Self-Medicating'
H Murphy, People, August 20, 2019 (Posted: Aug-21-2019 8AM)

UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety
Clinical Omics, August 2, 2019 (Posted: Aug-05-2019 8AM)

Blood samples reveal valuable data — and life-changing surprises for donors
PD McCluskey, Boston Globe, July 5, 2019 (Posted: Jul-09-2019 10AM)

More than 103,000 patients have agreed to provide blood to the Partners HealthCare Biobank, and their samples are providing valuable data for some 200 studies about Alzheimer?s, depression, diabetes, epilepsy, heart disease, and other conditions. But the research initiative is also having another impact, one that is more personal and immediate: It?s revealing genetic red flags that patients otherwise might never have seen.

Causal associations between potentially modifiable risk factors and the Alzheimer's phenome: A Mendelian randomization study
SJ Andrews et al, BioRXIV preprints, July 2 , 2019 (Posted: Jul-03-2019 8AM)

This study uses mendelian randomization to demonstrate a possible causal relationship between blood pressure, cholesterol levels, BMI, depression, insomnia symptoms, physical activity and educational attainment on Alzheimer's disease. These findings support public health programs to educate the public about preventable causes of AD.

Genetic and Environmental Risk Factors Associated With Trajectories of Depression Symptoms From Adolescence to Young Adulthood
ASF Kwong et al, JAMA Network Open, June 28, 2019 (Posted: Jun-28-2019 11AM)

In a cohort study of 3525 individuals observed from ages 10 to 24 years, both environmental risk factors and polygenic risk scores were associated with childhood-persistent and early-adult?onset trajectories of depression symptoms. Could these findings help to guide the timing and focus of prevention strategies?

How Artificial Intelligence Can Save Your Life
D Brooks, NY Times, June 24, 2019 (Posted: Jun-25-2019 9AM)

One area where A.I. can most immediately improve our lives may be in the area of mental health. Unlike many illnesses, there?s no simple physical test you can give someone to tell if he or she is suffering from depression.

A Waste of 1,000 Research Papers Decades of early research on the genetics of depression were built on non-existent foundations. How did that happen?
E Yong, The Atlantic, May 17, 2019 (Posted: May-17-2019 11AM)

Anxiety and depression in children: Get the facts
CDC, 2019 Brand (Posted: May-14-2019 7AM)

Association of Rare Copy Number Variants With Risk of Depression
KM Kendal et al. JAMA Psychiatry, April 17, 2019 (Posted: Apr-17-2019 1PM)

Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort.
Khandaker Golam M et al. Molecular psychiatry 2019 Mar (Posted: Mar-21-2019 8AM)

No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples.
Border Richard et al. The American journal of psychiatry 2019 Mar appiajp201818070881 (Posted: Mar-14-2019 8AM)

Insomnia tied to depression, cardiovascular disease
M Prize, Science, February 25, 2019 (Posted: Feb-25-2019 1PM)

Exercise May Help to Fend Off Depression
G Reynolds, NY Times, February 13, 2019 (Posted: Feb-20-2019 9AM)

Genetics of Depression Linked with Hundreds of Genes and Different Behavioral Traits
Gen News, February 6, 2019 (Posted: Feb-06-2019 10AM)

Investigating the Association Between Body Fat and Depression via Mendelian Randomization
M Speed et al, BioRXIV, February 3, 2019 (Posted: Feb-05-2019 2PM)

Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions
DM Howard et al, Nature Neurology, February 4, 2019 (Posted: Feb-04-2019 0PM)

Links between gut microbes and depression strengthened- The once-wild idea that intestinal bacteria influence mental health has transformed into a major research pursuit
Nature editorial, February 4, 2019 (Posted: Feb-04-2019 11AM)

Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults: A 2-Sample Mendelian Randomization Study.
Choi Karmel W et al. JAMA psychiatry 2019 Jan (Posted: Jan-25-2019 10AM)

A Mendelian Randomization Approach for Assessing the Relationship Between Physical Activity and Depression.
Chekroud Adam Mourad et al. JAMA psychiatry 2019 Jan (Posted: Jan-25-2019 10AM)

An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.
Sluiter Reinier L et al. The pharmacogenomics journal 2019 Jan (Posted: Jan-23-2019 1PM)

Genetic associations with suicide attempt severity and genetic overlap with major depression.
Levey Daniel F et al. Translational psychiatry 2019 Jan (1) 22 (Posted: Jan-19-2019 7AM)

Huge trove of British biodata is unlocking secrets of depression, sexual orientation, and more
J Kaiser et al, Science, January 3, 2019 (Posted: Jan-04-2019 9AM)

Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon Haley V et al. Psychiatry research 2018 Dec 271604-613 (Posted: Dec-19-2018 10AM)

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Bousman Chad A et al. Pharmacogenomics 2019 Jan 20(1) 37-47 (Posted: Dec-12-2018 10AM)

Pharmacogenomics and Biomarkers of Depression.
Jha Manish K et al. Handbook of experimental pharmacology 2018 Oct (Posted: Oct-24-2018 9AM)

Genome-wide meta-analysis of depression in 807,553 individuals identifies 102 independent variants with replication in a further 1,507,153 individuals
DM Howard et al, BioRXIV, October 9, 2018 (Posted: Oct-11-2018 7AM)

In the race to use genetic tests to predict whether antidepressants will work, science might be getting left behind
R Robbins, StatNews, September 28, 2018 (Posted: Sep-29-2018 0PM)

Genome-wide association study of suicide attempt in psychiatric disorders identifies association with major depression polygenic risk scores
N Mullins et al, BioRXIV Preprints, September 2018 (Posted: Sep-16-2018 2PM)

Does education protect against depression? Evidence from the Young Finns Study using Mendelian randomization.
Viinikainen Jutta et al. Preventive medicine 2018 Aug (Posted: Aug-28-2018 9AM)

DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies.
Story Jovanova Olivera et al. JAMA psychiatry 2018 Jul (Posted: Jul-17-2018 8AM)

New Genetic Links to Depression May Pave the Way for Novel Treatment Strategies
T Hampton, JAMA, July 3, 2018 (Posted: Jul-07-2018 5PM)

Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies.
Köhler Cristiano A et al. Journal of psychiatric research 2018 May 189-207 (Posted: Jun-12-2018 10AM)

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.
Wray Naomi R et al. Nature genetics 2018 Apr (Posted: May-01-2018 10AM)

Huge haul of ‘depression genes’ shows it’s a complex condition
New Scientist, Apr 27, 2018 (Posted: Apr-28-2018 1PM)

The use of polygenic risk scores to identify phenotypes associated with genetic risk of bipolar disorder and depression: A systematic review.
Mistry Sumit et al. Journal of affective disorders 2018 Feb 148-155 (Posted: Apr-01-2018 0PM)

What do the genetic association data say about the high risk of suicide in people with depression? A novel network-based approach to find common molecular basis for depression and suicidal behavior and related therapeutic targets.
Bozorgmehr Ali et al. Journal of affective disorders 2018 Jan 463-468 (Posted: Jan-23-2018 0PM)

Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder: a systematic and critical review.
Menezes Itiana Castro et al. Behavioural brain research 2018 Jan (Posted: Jan-23-2018 0PM)

Battling depression with pharmacogenetics: Genetic screening could eliminate trial-and-error approach to medications
R Lewis, Genetic Literacy Project, Jan 23, 2018 (Posted: Jan-23-2018 0PM)

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug Classes
BioRxiV, Sep 8,, 2017 (Posted: Sep-09-2017 0PM)

Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence.
Andersen Allan M et al. JAMA psychiatry 2017 Aug (Posted: Aug-21-2017 11AM)

Genetics of Depression: Progress at Last.
Mullins Niamh et al. Current psychiatry reports 2017 Aug (8) 43 (Posted: Aug-11-2017 1PM)

Preventing Suicide
Risk factors include family history of suicide Brand (Posted: Aug-11-2017 1PM)

Genomewide association study identifies 30 loci associated with bipolar disorder
E Stahl et al, BioRxIV, AUgust 2017 (Posted: Aug-11-2017 1PM)

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression
N Wray et al, BioRXiV, July 2017 (Posted: Jul-24-2017 11AM)

The Stratification Of Major Depressive Disorder Into Genetic Subgroups
DM Howard et al, BioXRIV, May 2017 (Posted: May-05-2017 6PM)

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses And Testing For Enrichment Of Psychiatric Drug Classes
HC So, BioXRIV, May 2017 (Posted: May-03-2017 6PM)

Finding the Genes of Depression
F Addison, Front Line Genomics, April 2017, (Posted: Apr-06-2017 8AM)

Systematic review and meta-analysis of genetic studies of late-life depression.
Tsang Ruby S M et al. Neuroscience and biobehavioral reviews 2017 Apr 129-139 (Posted: Apr-05-2017 11AM)

Pharmacogenomic aspects of bipolar disorder: An update.
Budde M et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2017 Mar (Posted: Apr-05-2017 11AM)

Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
Rosenblat Joshua D et al. The Journal of clinical psychiatry 2017 Jan (Posted: Jan-11-2017 9AM)

Family history and perceived risk of diabetes, cardiovascular disease, cancer and depression.
Vornanen Marleena et al. Preventive medicine 2016 Jun (Posted: Jul-06-2016 10AM)

Can a Genetic Test Determine the Best Medications for My Son?
Dear Jeannie, NSGC blog post, June 2016 (Posted: Jun-15-2016 7AM)

Implementing Recommendations for Depression Screening of Adults
HS Mayberg, JAMA Neurology, January 26, 2016 (Posted: Jan-27-2016 1PM)

Depression: what you need to know
Many factors may play a role in depression, including genetics, brain biology and chemistry, and life events, NIMH Web Page Brand (Posted: Jan-27-2016 9AM)

more


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP